Hypercalcemia Management in Hypophosphatasia
Refractory hypercalcemia and hypercalciuria in hypophosphatasia are typically resistant to hydration and loop diuretic therapy. [1]
Bisphosphonates are contraindicated/relatively contraindicated in hypophosphatasia because of theoretical risk related to inhibition of alkaline phosphatase activity and potential exacerbation of the underlying mineralization defect. [1]
Asfotase alfa (enzyme replacement therapy) is recommended to improve calcium homeostasis and bone-related outcomes in appropriate pediatric phenotypes. [1]
Medication Avoidance and Contraindications
-
Bisphosphonates are contraindicated/relatively contraindicated in hypophosphatasia. [1]
-
Excess vitamin D should be avoided because it can exacerbate hypercalcemia and hypercalciuria in infantile hypophosphatasia. [1]
Initial Assessment and Monitoring
-
Ionized calcium (or serum calcium adjusted for albumin concentration) and serum phosphorus should be monitored to characterize calcium homeostasis. [1]
-
Urine calcium-to-creatinine ratio should be monitored to assess for nephrocalcinosis during calcium management. [1]
-
Serum PTH and 25-hydroxyvitamin D should be evaluated to guide ongoing management of mineral metabolism. [1]
Supportive Measures for Calcium Homeostasis
-
Hydration and furosemide are not reliably effective in resolving recalcitrant hypercalcemia and hypercalciuria in hypophosphatasia. [1]
-
Calcium homeostasis management should be coordinated with endocrinology and nephrology because hypercalcemia may be complicated by renal involvement. [1]
Enzyme Replacement Therapy Role
-
Asfotase alfa is used to address the underlying disease mechanism and has been shown to improve calcium homeostasis in hypophosphatasia patients. [1]
-
Ongoing monitoring is required during asfotase alfa therapy using calcium and mineral metabolism measurements. [1]
Stepwise Escalation for Persistent or Severe Hypercalcemia
-
For recalcitrant hypercalcemia/hypercalciuria that is resistant to hydration and furosemide, alternative strategies should prioritize avoidance of contraindicated agents and optimization of disease-directed therapy. [1]
-
Management escalation should include reassessment for nephrocalcinosis and other end-organ effects using renal evaluation and urine calcium monitoring. [1]
Common Pitfalls to Avoid
-
Administration of bisphosphonates for hypercalcemia in hypophosphatasia should be avoided because bisphosphonates are relatively contraindicated in this disorder. [1]
-
Use of vitamin D supplementation without close specialist monitoring should be avoided in settings where hypercalcemia/hypercalciuria risk is present. [1]
Targets and Goals of Therapy
-
The management goal is stabilization of calcium homeostasis and prevention of renal complications during hypophosphatasia care. [1]
-
Serial monitoring of calcium indices and urine calcium measures is used to guide achievement and maintenance of stable mineral metabolism. [1]